JO3794B1 - المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون - Google Patents
المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتونInfo
- Publication number
- JO3794B1 JO3794B1 JOP/2016/0256A JOP20160256A JO3794B1 JO 3794 B1 JO3794 B1 JO 3794B1 JO P20160256 A JOP20160256 A JO P20160256A JO 3794 B1 JO3794 B1 JO 3794B1
- Authority
- JO
- Jordan
- Prior art keywords
- bruton
- inhibitors
- tyrosine kinase
- polycyclic compounds
- compounds
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000003367 polycyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
الاختراع الحالي موجه لمركبات الصيغة (I) وأساليب استخدامها وتحضيرها، فضلاً عن التركيبات التي تتكون منها مركبات الصيغة (I). (I)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265836P | 2015-12-10 | 2015-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3794B1 true JO3794B1 (ar) | 2021-01-31 |
Family
ID=57681784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2016/0256A JO3794B1 (ar) | 2015-12-10 | 2016-12-08 | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10717745B2 (ar) |
| EP (2) | EP3386991B1 (ar) |
| JP (2) | JP6835846B2 (ar) |
| KR (1) | KR102103395B1 (ar) |
| CN (2) | CN113121562B (ar) |
| AR (1) | AR107042A1 (ar) |
| AU (1) | AU2016366541B2 (ar) |
| BR (1) | BR112018011526B1 (ar) |
| CA (1) | CA3007990C (ar) |
| CY (1) | CY1123263T1 (ar) |
| DK (1) | DK3386991T3 (ar) |
| EA (1) | EA035168B1 (ar) |
| ES (1) | ES2805835T3 (ar) |
| HR (1) | HRP20201193T1 (ar) |
| HU (1) | HUE049502T2 (ar) |
| IL (1) | IL259863B (ar) |
| JO (1) | JO3794B1 (ar) |
| LT (1) | LT3386991T (ar) |
| MA (2) | MA53110A (ar) |
| MD (1) | MD3386991T2 (ar) |
| ME (1) | ME03803B (ar) |
| MX (1) | MX387590B (ar) |
| PL (1) | PL3386991T3 (ar) |
| PT (1) | PT3386991T (ar) |
| RS (1) | RS60604B1 (ar) |
| SI (1) | SI3386991T1 (ar) |
| SM (1) | SMT202000404T1 (ar) |
| TW (1) | TWI729047B (ar) |
| UY (1) | UY37015A (ar) |
| WO (1) | WO2017100662A1 (ar) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3793B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3596087A1 (en) * | 2017-03-15 | 2020-01-22 | Janssen Sciences Ireland Unlimited Company | Methods of selective aryl- and heteroaryl-nitrogen bond formation |
| CN108164397B (zh) * | 2018-01-18 | 2020-11-13 | 暨南大学 | 一类邻苯二酚衍生物及其制备方法 |
| MA52780A (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| WO2021139717A1 (zh) * | 2020-01-07 | 2021-07-15 | 南京明德新药研发有限公司 | 氘代噻吩并吡啶类化合物 |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| US20230013755A1 (en) * | 2021-06-04 | 2023-01-19 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| AU2022305095A1 (en) | 2021-06-30 | 2024-02-15 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| CN117794540A (zh) | 2021-08-09 | 2024-03-29 | 詹森药业有限公司 | 用于治疗b细胞恶性肿瘤的组合物 |
| CA3252338A1 (en) * | 2022-02-18 | 2023-08-24 | Janssen Pharmaceutica Nv | SYNTHESIS OF BRUTON TYROSINE KINASE INHIBITORS |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3112415A1 (de) | 1981-03-28 | 1982-10-07 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden |
| US5430150A (en) | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
| US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| JP2008513463A (ja) | 2004-09-15 | 2008-05-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チアゾロピリジンキナーゼ阻害剤 |
| US7579356B2 (en) | 2005-05-04 | 2009-08-25 | Janssen Pharmaceutica Nv | Thia-tetraazaacenaphthylene kinase inhibitors |
| US7605154B2 (en) | 2005-08-08 | 2009-10-20 | Janssen Pharmaceutica N.V. | Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors |
| US7427625B2 (en) * | 2006-02-08 | 2008-09-23 | Janssen Pharmaceutica, N.V. | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors |
| PT2201840E (pt) | 2006-09-22 | 2012-02-14 | Pharmacyclics Inc | Inibidores da tirosina quinase de bruton |
| WO2010056875A1 (en) * | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| JP5739334B2 (ja) * | 2009-08-26 | 2015-06-24 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| WO2011133609A2 (en) | 2010-04-19 | 2011-10-27 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of btk inhibitors |
| FR2978441A1 (fr) | 2011-07-25 | 2013-02-01 | Diverchim | Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques |
| MX380171B (es) | 2013-03-15 | 2025-03-12 | Janssen Pharmaceutica Nv | Procesos e intermedios para preparar un medicamento. |
| CN109096274B (zh) * | 2013-12-11 | 2022-07-01 | 比奥根Ma公司 | 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物 |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| WO2018103058A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| WO2018103060A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2016
- 2016-12-08 JO JOP/2016/0256A patent/JO3794B1/ar active
- 2016-12-09 ES ES16820106T patent/ES2805835T3/es active Active
- 2016-12-09 KR KR1020187018900A patent/KR102103395B1/ko active Active
- 2016-12-09 EP EP16820106.9A patent/EP3386991B1/en active Active
- 2016-12-09 EP EP20177012.0A patent/EP3719022A1/en active Pending
- 2016-12-09 EA EA201891378A patent/EA035168B1/ru unknown
- 2016-12-09 PT PT168201069T patent/PT3386991T/pt unknown
- 2016-12-09 MX MX2018007075A patent/MX387590B/es unknown
- 2016-12-09 CN CN202110404024.3A patent/CN113121562B/zh active Active
- 2016-12-09 HR HRP20201193TT patent/HRP20201193T1/hr unknown
- 2016-12-09 SM SM20200404T patent/SMT202000404T1/it unknown
- 2016-12-09 SI SI201630825T patent/SI3386991T1/sl unknown
- 2016-12-09 BR BR112018011526-6A patent/BR112018011526B1/pt active IP Right Grant
- 2016-12-09 WO PCT/US2016/065954 patent/WO2017100662A1/en not_active Ceased
- 2016-12-09 AU AU2016366541A patent/AU2016366541B2/en active Active
- 2016-12-09 JP JP2018530000A patent/JP6835846B2/ja active Active
- 2016-12-09 UY UY0001037015A patent/UY37015A/es active IP Right Grant
- 2016-12-09 CN CN201680072125.2A patent/CN108884106A/zh active Pending
- 2016-12-09 ME MEP-2020-155A patent/ME03803B/me unknown
- 2016-12-09 MA MA053110A patent/MA53110A/fr unknown
- 2016-12-09 PL PL16820106T patent/PL3386991T3/pl unknown
- 2016-12-09 HU HUE16820106A patent/HUE049502T2/hu unknown
- 2016-12-09 MD MDE20180978T patent/MD3386991T2/ro unknown
- 2016-12-09 MA MA43409A patent/MA43409B1/fr unknown
- 2016-12-09 DK DK16820106.9T patent/DK3386991T3/da active
- 2016-12-09 US US15/374,905 patent/US10717745B2/en active Active
- 2016-12-09 LT LTEP16820106.9T patent/LT3386991T/lt unknown
- 2016-12-09 CA CA3007990A patent/CA3007990C/en active Active
- 2016-12-09 RS RS20200884A patent/RS60604B1/sr unknown
- 2016-12-09 TW TW105140760A patent/TWI729047B/zh active
- 2016-12-12 AR ARP160103789A patent/AR107042A1/es active IP Right Grant
-
2018
- 2018-06-07 IL IL259863A patent/IL259863B/en active IP Right Grant
-
2019
- 2019-05-15 US US16/413,453 patent/US10934310B2/en active Active
-
2020
- 2020-05-13 US US15/931,437 patent/US11319329B2/en active Active
- 2020-08-18 CY CY20201100769T patent/CY1123263T1/el unknown
-
2021
- 2021-02-04 JP JP2021016602A patent/JP7072690B2/ja active Active
-
2022
- 2022-03-25 US US17/705,225 patent/US12065446B2/en active Active
-
2024
- 2024-07-03 US US18/763,484 patent/US20240383914A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3794B1 (ar) | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون | |
| MX386700B (es) | Inhibidores de la tirosina quinasa de bruton y metodos de su uso. | |
| MX2020001598A (es) | Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5). | |
| NZ729603A (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
| PH12019550235A1 (en) | Kinase inhibitors and uses thereof | |
| MY179781A (en) | Biaryl inhibitors of bruton's tyrosine kinase | |
| PH12016500531B1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| EA201492056A1 (ru) | Пиримидиниловые ингибиторы тирозинкиназы | |
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| TN2016000238A1 (en) | Tricyclic compounds as anticancer agents. | |
| EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов | |
| MX2017003254A (es) | 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina. | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| CA3056612A1 (en) | Analogs of deutetrabenazine, their preparation and use | |
| EA201600002A1 (ru) | Производные пролекарства замещенных триазолопиридинов | |
| EA201992728A1 (ru) | Ингибиторы киназы и способы их применения |